ATE509269T1 - Verfahren und verbindungen zur modulierung von apoptosis - Google Patents

Verfahren und verbindungen zur modulierung von apoptosis

Info

Publication number
ATE509269T1
ATE509269T1 AT04796496T AT04796496T ATE509269T1 AT E509269 T1 ATE509269 T1 AT E509269T1 AT 04796496 T AT04796496 T AT 04796496T AT 04796496 T AT04796496 T AT 04796496T AT E509269 T1 ATE509269 T1 AT E509269T1
Authority
AT
Austria
Prior art keywords
methods
compounds
modulating apoptosis
apoptosis
modulating
Prior art date
Application number
AT04796496T
Other languages
English (en)
Inventor
Amy Lee
Original Assignee
Univ Southern California
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Southern California filed Critical Univ Southern California
Application granted granted Critical
Publication of ATE509269T1 publication Critical patent/ATE509269T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4747—Apoptosis related proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Zoology (AREA)
  • Biochemistry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Toxicology (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Diabetes (AREA)
  • Biomedical Technology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Cardiology (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • Obesity (AREA)
  • Vascular Medicine (AREA)
  • Endocrinology (AREA)
  • Emergency Medicine (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
AT04796496T 2003-10-27 2004-10-26 Verfahren und verbindungen zur modulierung von apoptosis ATE509269T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US51466103P 2003-10-27 2003-10-27
PCT/US2004/035575 WO2005045428A2 (en) 2003-10-27 2004-10-26 Methods and compositions for modulating apoptosis

Publications (1)

Publication Number Publication Date
ATE509269T1 true ATE509269T1 (de) 2011-05-15

Family

ID=34572765

Family Applications (1)

Application Number Title Priority Date Filing Date
AT04796496T ATE509269T1 (de) 2003-10-27 2004-10-26 Verfahren und verbindungen zur modulierung von apoptosis

Country Status (7)

Country Link
US (3) US20050143291A1 (de)
EP (1) EP1678497B1 (de)
JP (2) JP2007509616A (de)
AT (1) ATE509269T1 (de)
AU (2) AU2004288166B2 (de)
CA (1) CA2543719A1 (de)
WO (1) WO2005045428A2 (de)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2004005351A2 (en) 2002-07-04 2004-01-15 Oncomab Gmbh Neoplasm specific antibodies and uses thereof
DE10311248A1 (de) 2003-03-14 2004-09-30 Müller-Hermelink, Hans Konrad, Prof. Dr. Humaner monoklonaler Antikörper
EP1531162A1 (de) 2003-11-14 2005-05-18 Heinz Vollmers Antikörper SAM-6, der spezifisch von Adenocarzinom ist, und dessen Verwendungen
DE10353175A1 (de) 2003-11-14 2005-06-16 Müller-Hermelink, Hans Konrad, Prof. Dr. Humaner monoklonaler Antikörper mit fettsenkender Wirkung
JP2007033041A (ja) * 2005-07-22 2007-02-08 Sumitomo Chemical Co Ltd 胎盤型グルタチオン−ｓ−トランスフェラ−ゼ酵素を認識する抗体に対して陰性を示すラット肝臓腫瘍性病変又は前腫瘍性病変の検定方法
CN100419078C (zh) * 2005-11-18 2008-09-17 李川源 一种表达糖调节蛋白的方法及其应用
AU2007305166A1 (en) * 2006-10-03 2008-04-10 University Of Southern California GRP78 as a predictor of responsiveness to therapeutic agents
JP5374360B2 (ja) * 2007-02-27 2013-12-25 中外製薬株式会社 抗ｇｒｐ７８抗体を有効成分として含む医薬組成物
WO2009026496A1 (en) * 2007-08-22 2009-02-26 University Of Southern California Grp78 and tumor angiogenesis
EP2239571A1 (de) * 2009-04-10 2010-10-13 PamGene B.V. Verfahren zur Profilierung von Wirkstoffverbindungen mit Proteinkinasehemmern
WO2012097255A2 (en) * 2011-01-14 2012-07-19 Scott & White Healthcare Therapeutic effect of heat shock proteins in preventing amylin aggregation in type 2 diabetes mellitus
WO2017161202A1 (en) * 2016-03-17 2017-09-21 University Of Southern California Src inhibitor to block cell surface grp78 expression

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5196523A (en) * 1985-01-01 1993-03-23 The University Of Southern California Control of gene expression by glucose, calcium and temperature
US4912040A (en) * 1986-11-14 1990-03-27 Genetics Institute, Inc. Eucaryotic expression system
US6761892B1 (en) * 1995-08-18 2004-07-13 Sloan-Kettering Institute For Cancer Research Heat shock protein-based vaccines and immunotherapies
CN1063957C (zh) * 1997-09-29 2001-04-04 北京华颐中药制药厂 一种金荞麦制剂的制备方法
EP0927757A1 (de) * 1997-12-03 1999-07-07 Leadd B.V. Verfahren und Mitteln um Apoptose zu induzieren durch Interferenz mit Bip-ähnliche Proteine
US7049132B1 (en) * 1999-06-28 2006-05-23 University Of Southern California Stress-responsive induction of a therapeutic agent and methods of use
US7179481B2 (en) * 2002-09-19 2007-02-20 Kimberly-Clark Worldwide, Inc. Vaginal health products
US20050053993A1 (en) * 2002-12-18 2005-03-10 Davidson Donald J. Uses of an endothelial cell receptor
US20050123571A1 (en) * 2003-06-06 2005-06-09 Rossini Aldo A. Modulation of apoptosis
US20080075664A1 (en) * 2006-09-01 2008-03-27 University Of Southern California Control Of Diabetes And Obesity

Also Published As

Publication number Publication date
US20120251543A1 (en) 2012-10-04
US20050143291A1 (en) 2005-06-30
EP1678497B1 (de) 2011-05-11
AU2004288166B2 (en) 2008-12-18
JP2007509616A (ja) 2007-04-19
CA2543719A1 (en) 2005-05-19
WO2005045428A2 (en) 2005-05-19
US20110217314A1 (en) 2011-09-08
AU2004288166A1 (en) 2005-05-19
AU2009201077A1 (en) 2009-04-23
EP1678497A2 (de) 2006-07-12
JP2010233569A (ja) 2010-10-21
WO2005045428A3 (en) 2005-10-20

Similar Documents

Publication Publication Date Title
UA83194C2 (ru) Производные пиримидина и их применение как модуляторов св2
CY1109104T1 (el) 1,2,3,4 τετρα-υποκατεστημενη ινδολη για την αντιμετωπιση ασθενειων του αναπνευστικου
EA200601798A1 (ru) Замещенные соединения морфолина для лечения расстройств центральной нервной системы
ATE429645T1 (de) Verwendung von eph-rezeptor-inhibitoren zur behandlung neurodegenerativer krankheiten
ATE345329T1 (de) Pyridinderivate als modulatoren des cb2-rezeptors
ATE453653T1 (de) Platinkomplexe zur behandlung von tumoren
DE502005008971D1 (de) Substituierte 1,4,8-triazaspiroä4.5 decan-2-on-verbindungen zur behandlung von fettsucht
SE0301010D0 (sv) Novel compounds
ATE534730T1 (de) Diagnose und behandlung von multiplen sulfatase- erkrankungen und anderen mit hilfe eines formylglycin bildenden enzyms
SE0202241D0 (sv) Novel Compounds
NO20061845L (no) Fenyl-piperazinderivater som modulatorer for muskarine reseptorer
ATE509269T1 (de) Verfahren und verbindungen zur modulierung von apoptosis
WO2004024097A8 (en) Compositions and methods for the treatment of immune related diseases
DE602005004268D1 (de) 1-(1h-indol-1-yl)-3-(4-methylpiperazin-1-yl)-1-phenylpropan-2-olderivate und verwandte verbindungen als modulatoren der norepinephrin-(ne-) und der serotonin-(5-ht-) aktivität und der monoaminwiederaufnahme zur behandlung von vasomotorischen symptomen (vms)
MY141528A (en) Anilinopyrazole derivatives useful for the treatment of diabetes
AU2003260436A1 (en) Pyrimidine compounds
ATE302002T1 (de) Verwendung von pyrazolderivaten zur behandlung von unfruchtbarkeit
DE60326248D1 (de) Verbindungen, zusammensetzungen und verfahren zur behandlung von zellulären proliferativen erkrankungen
NO20061015L (no) Fremgangsmate for rensing av et ikke-immunglobulinprotein som omfatter et immunglobulinlignende (Ig-lignende) domene
SG144140A1 (en) Emulsifying systems containing azetidine derivatives
DE60323234D1 (de) Verwendung von Vitamin C zur Behandlung der Charcot-Marie-Tooth Krankheit
CY1110156T1 (el) Υποκατεστημενες ενωσεις 4,5,6,7-τετραϋδρο-βενζοθειαζολ-2-υλαμινης
DK1656360T3 (da) Thiazolinderivater som selektive androgenreceptor-modulatorer
ATE503476T1 (de) Zusammensetzungen und verfahren zur behandlung von krankheiten, die durch infektion mit yersinia spp ausgelöst sind
ATE417035T1 (de) Vitamin-d3-analoga zur prävention undbehandlung von knochenerkrankungen

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties